Leap therapeutics news Results

You are searching for Leap therapeutics news, Below listing suggest some keywords related this keyword and listing websites with same content

Find Top Domain Names With

Top Keywords Suggestions

1 Leap therapeutics news
2 Leap therapeutics stock news

Most Searched Keywords

Domains Actived Recently

   » Youl.ink (9 seconds ago)

   » Sabanasantaexpo.com (4 seconds ago)

   » Foxadvantage.com (3 seconds ago)

   » Coreworx.com (6 seconds ago)

   » 1stclass-bass.com (2 seconds ago)

   » Dailymemphian.com (8 seconds ago)

   » Caircapitolday.com (6 seconds ago)

   » Simonebeneventi.com (6 seconds ago)

   » Jhmeier.com (2 seconds ago)

   » Bimthoughts.com (4 seconds ago)

Extract All Emails from Any Domain

Find All Domains on Any IP/ Domain

About 48 Websites Link


LPTX News Today (Leap Therapeutics) MarketBeat

Marketbeat.com   DA: 18 PA: 25 MOZ Rank: 43

  • Leap Therapeutics (NASDAQ LPTX) News Headlines Today
  • Source: Source Headline; Down 19.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Leap Therapeutics, Inc
  • (LPTX) finance.yahoo.com - July 19 at 1:12 PM: Brokerages Anticipate Leap Therapeutics, Inc
  • (NASDAQ:LPTX) Will Announce Quarterly Sales of $380,000.00

Leap Therapeutics, Inc. (LPTX) Latest Stock News

Finance.yahoo.com   DA: 17 PA: 17 MOZ Rank: 35

Get the latest Leap Therapeutics, Inc. (LPTX) stock news and headlines to help you in your trading and investing decisions.

Leap Therapeutics To Present At The ESMO 2021 Virtual

Markets.businessinsider.com   DA: 27 PA: 50 MOZ Rank: 79

  • Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting

Leap Therapeutics : And Flagship Biosciences Develop Image

Marketscreener.com   DA: 22 PA: 50 MOZ Rank: 75

  • and WESTMINSTER, Colo., May 12, 2021 /PRNewswire/ -- Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced that they have developed an image analysis RNAscope ® assay that is …

LPTX Stock Forecast, Price & News (Leap Therapeutics)

Marketbeat.com   DA: 18 PA: 20 MOZ Rank: 42

  • Leap Therapeutics' stock was trading at $2.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO)
  • Since then, LPTX stock has decreased by 27.9% and is now trading at $1.45
  • View which stocks have been most impacted by COVID-19.

Leap Therapeutics Initiates Trial, And Other News: The

Seekingalpha.com   DA: 16 PA: 50 MOZ Rank: 71

  • Leap Therapeutics Initiates Trial, And Other News: The Good, Bad And Ugly Of Biopharma Sep
  • 25, 2020 3:42 PM ET Leap Therapeutics, Inc

LEAP Program California EDD

Edd.ca.gov   DA: 14 PA: 27 MOZ Rank: 47

  • The Limited Examination and Appointment Program (LEAP) is a recruitment and hiring program for individuals with disabilities
  • Instead of taking the traditional state civil service exam, you can show your knowledge and skills for a position through on-the-job testing.

News Releases Leap Therapeutics, Inc.

Investors.leaptx.com   DA: 20 PA: 27 MOZ Rank: 54

  • Leap Therapeutics to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
  • Leap Therapeutics to Present at Raymond James 2021 Virtual Human Health Innovation Conference
  • Leap Therapeutics Reports First Quarter 2021 Financial Results

Leap Therapeutics : To Present At Ladenburg Thalmann 2021

Marketscreener.com   DA: 22 PA: 50 MOZ Rank: 80

  • CAMBRIDGE, Mass., July 7, 2021 /PRNewswire/ -- Leap Therapeutics, Inc
  • , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E

Leap Therapeutics, Inc. (LPTX) Stock Price, News, Quote

Finance.yahoo.com   DA: 17 PA: 12 MOZ Rank: 38

  • Find the latest Leap Therapeutics, Inc
  • (LPTX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Leap Therapeutics To Present At The ESMO 2021 Virtual

Wfmz.com   DA: 12 PA: 50 MOZ Rank: 72

  • CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- Leap Therapeutics, Inc
  • (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the

Leap Therapeutics And BeiGene Announce Exclusive Option

Investors.leaptx.com   DA: 20 PA: 50 MOZ Rank: 81

  • Leap Therapeutics (Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator
  • DKN-01 is in clinical trials in patients with esophagogastric

Leap Therapeutics To Present At Raymond James 2021 Virtual

Wfmz.com   DA: 12 PA: 50 MOZ Rank: 74

  • Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting

LPTX Stock Price Leap Therapeutics Inc. Stock Quote (U.S

Marketwatch.com   DA: 19 PA: 21 MOZ Rank: 53

  • LPTX | Complete Leap Therapeutics Inc
  • View real-time stock prices and stock quotes for a full financial overview.

Leap Therapeutics To Present At The ESMO 2021 Virtual Congress

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 82

  • Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting

Investors Leap Therapeutics, Inc.

Investors.leaptx.com   DA: 20 PA: 20 MOZ Rank: 55

  • Leap Therapeutics to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
  • Leap Therapeutics to Present at Raymond James 2021 Virtual Human Health Innovation Conference
  • Leap Therapeutics Reports First Quarter 2021 Financial Results.

Leap Therapeutics (LPTX) Stock Price, Quote & News Stock

Stockanalysis.com   DA: 17 PA: 13 MOZ Rank: 46

  • Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer
  • Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer.

Leap Therapeutics And BeiGene Announce Exclusive Option

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 85

  • LEAP THERAPEUTICS CONTACTS: Douglas E
  • Onsi Chief Financial Officer Leap Therapeutics, Inc
  • 617-714-0360 [email protected] Heather Savelle Investor Relations Argot Partners 212-600-1902 [email

Leap Therapeutics : Completes Enrollment In Gastric

Marketscreener.com   DA: 22 PA: 50 MOZ Rank: 90

  • All news about LEAP THERAPEUTICS, INC
  • 07/07: LEAP THERAPEUTICS: to Present at Ladenburg Thalmann 2021 Virtual Healthcare Con.
  • 06/16: LEAP THERAPEUTICS, INC.: Submission of Matters to a Vote of Security Holders (f.

Leap Therapeutics To Present At The ESMO 2021 Virtual

Markets.ft.com   DA: 14 PA: 21 MOZ Rank: 54

  • CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- Leap Therapeutics, Inc
  • (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting initial data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination …

Presentations And Events Leap Therapeutics, Inc.

Investors.leaptx.com   DA: 20 PA: 37 MOZ Rank: 77

  • Wainwright Virtual BioConnect Conference
  • Piper Sandler 32nd Annual Virtual Healthcare Conference Fireside Chat
  • Stifel 2020 Virtual Healthcare Conference

About Leap Therapeutics

Leaptx.com   DA: 14 PA: 7 MOZ Rank: 42

Leap Therapeutics Announces Orphan Drug Designation of DKN-01 for the Treatment of Gastric/Gastroesophageal Junction Cancer and Closes $45 million Public Offering of Common Stock Board of Directors Chris Mirabelli, Ph.D.

Leap Therapeutics In The News LPTX

Macroaxis.com   DA: 17 PA: 17 MOZ Rank: 56

  • Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Leap Therapeutics and other traded companies coverage
  • We help investors stay connected with Leap Therapeutics headlines for the 26th of July to make an informed investment decision based on correlating the impacts of news items on Leap Therapeutics Stock performance.

Leap Therapeutics To Present At Ladenburg Thalmann 2021

Wfmz.com   DA: 12 PA: 50 MOZ Rank: 85

  • Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting

Leap Therapeutics News

Ih.advfn.com   DA: 12 PA: 50 MOZ Rank: 86

  • 1.46 0.05 (3.55%) Upgrade to Real-Time Afterhours (Closed) Leap Therapeutics to Present at Raymond James 2021 Virtual Human Health Innovation Conference June 14 2021 - 07:00AM PR Newswire (US) CAMBRIDGE

Leap Therapeutics To Present At 39th Annual J.P. Morgan

Wfmz.com   DA: 12 PA: 50 MOZ Rank: 87

  • Leap Therapeutics (Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting

Leap Therapeutics Reports First Quarter 2021 Financial

Marketwatch.com   DA: 19 PA: 50 MOZ Rank: 95

  • Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting

Leap Therapeutics (NasdaqGM:LPTX)

Simplywall.st   DA: 13 PA: 50 MOZ Rank: 90

  • How has Leap Therapeutics's share price performed over time and what events caused price changes? Latest Share Price and Events
  • Stable Share Price: LPTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- …

Pipeline Leap Therapeutics

Leaptx.com   DA: 14 PA: 13 MOZ Rank: 55

  • DKN-01 is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein
  • DKN-01 is in clinical trials for gastroesophageal, hepatobiliary, gynecologic, and prostate cancer
  • During the 35th annual SITC meeting, on November 11-14, 2020, Leap Therapeutics presents updated data for DKN-01 in esophagogastric cancer patients.

Leap Therapeutics News

Ih.advfn.com   DA: 12 PA: 50 MOZ Rank: 91

  • Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein
  • DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and

Leap Therapeutics LPTX License Agreement And Offering +53%

Biopharmcatalyst.com   DA: 24 PA: 50 MOZ Rank: 20

  • (Nasdaq: LPTX) shares closed up 53% to $1.61 following its announcement it will receive an upfront payment of $3m following a license agreement with BeiGene, Ltd
  • (Nasdaq: BGNE) for the development of its pipeline candidate DKN-01, in Asia (excluding Japan), Australia, and New Zealand.

LPTX Leap Therapeutics Inc. Stock Price & News

Wsj.com   DA: 11 PA: 24 MOZ Rank: 66

  • News Leap Therapeutics Inc.LPTX
  • The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per

Leap Therapeutics Reports First Quarter 2021 Financial Results

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 100

  • Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics
  • Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting

Leap Therapeutics News: LPTX Stock Takes A Massive 58%

Investorplace.com   DA: 17 PA: 50 MOZ Rank: 100

  • The Leap Therapeutics news release notes that the two companies will also be working together on a new study
  • This will seek to combine DKN-01 with BeiGene’s anti-PD-1 …

Science Leap Therapeutics

Leaptx.com   DA: 14 PA: 9 MOZ Rank: 57

  • Dickkopf-related protein 1 (DKK1) is a protein that regulates Wnt signaling pathways
  • Aberrant Wnt signaling is often implicated in cancer, enabling cancer cells to grow and divide and to suppress the immune system
  • Published data indicates that DKK1 is often overexpressed in many cancers and is associated with worse outcomes

Leap Therapeutics Stock Quote. LPTX

Ih.advfn.com   DA: 12 PA: 50 MOZ Rank: 97

  • Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells
  • Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1.

Leap Therapeutics Reports Second Quarter 2020 Financial

Prnewswire.com   DA: 18 PA: 50 MOZ Rank: 14

  • 13, 2020 /PRNewswire/ -- Leap Therapeutics, Inc
  • (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported

Recently Analyzed Sites

Youl.ink (9 seconds ago)

Sabanasantaexpo.com (4 seconds ago)

Foxadvantage.com (3 seconds ago)

Coreworx.com (6 seconds ago)

1stclass-bass.com (2 seconds ago)

Dailymemphian.com (8 seconds ago)

Caircapitolday.com (6 seconds ago)

Simonebeneventi.com (6 seconds ago)

Jhmeier.com (2 seconds ago)

Bimthoughts.com (4 seconds ago)

Geeksandgurus.com (12 seconds ago)

Cvriskcalculator.com (3 seconds ago)

Benthanh-toyotavn.com (19 seconds ago)

Yy9799.com (0 seconds ago)

Winterwoodonline.com (6 seconds ago)

Stlfoodbank.org (7 seconds ago)

4monimo.com (21 seconds ago)

Justsaynews.com (8 seconds ago)